New hope against drug-resistant lung bacteria? rifabutin trial begins
NCT ID NCT07514364
First seen Apr 12, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tests whether the antibiotic rifabutin can improve treatment for people with lung infections caused by Mycobacterium abscessus that are resistant to the common antibiotic clarithromycin. About 60 adults with active lung disease will receive rifabutin as part of their therapy. The goal is to see if rifabutin can overcome the bacteria's resistance and lead to better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM ABSCESSUS LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital Yunlin Branch
RECRUITINGDouliu, Yunlin County, 640, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.